lunes, 31 de julio de 2017

ProMED-mail | EASTERN EQUINE ENCEPHALITIS - USA (05): (WISCONSIN) EQUINE

ProMED-mail

ProMED logo    ISID logo

« prev

ProMED logo    ISID logo



Published Date: 2017-07-30 20:23:35
Subject: PRO/AH/EDR> Eastern equine encephalitis - USA (05): (WI) equine
Archive Number: 20170730.5216046

EASTERN EQUINE ENCEPHALITIS - USA (05): (WISCONSIN) EQUINE
**********************************************************
A ProMED-mail post
http://www.promedmail.org
ProMED-mail is a program of the
International Society for Infectious Diseases
http://www.isid.org

Date: 28 Jul 2017
Source: Wisconsin State Journal [edited]
http://host.madison.com/wsj/news/local/two-horses-die-of-severe-mosquito-borne-virus/article_e5fbffd7-5307-5dfe-8945-4820568ffdd4.html


Two horses died this week after being infected with eastern equine encephalitis virus (EEE or EEEv), a severe, mosquito-borne disease, in the Tomah area, according to the Wisconsin Veterinary Diagnostic Lab.

The lab, housed at UW-Madison, discovered eastern equine encephalitis virus in the brain tissue of the horses, which were last vaccinated in the fall of 2016. The virus is deadly in horses about 90 percent of the time.

The disease can also be transmitted to humans, in rare cases. The virus, which is typically transmitted between birds, can be carried to and between horses and humans via mosquitoes. If a human contracts the virus, there is a 33 percent mortality rate, with a risk of significant brain damage in many survivors, according to the Centers for Disease Control and Prevention.

The spread of the virus is prompted by especially warm and humid weather. Last year [2016], the virus infected 19 horses in 11 Wisconsin counties, according to the Department of Agriculture, Trade and Consumer Protection.

Keith Poulsen, a large animal veterinarian at the lab, recommends that horses be vaccinated in the spring, to prepare for mosquito season.

This is the 2nd time in the past week that horses have died of mosquito-borne viruses.

The Department of Agriculture, Trade and Consumer Protection announced on Monday [24 Jul 2017] that a horse was euthanized in central Wisconsin after being infected with the West Nile virus.

[Byline: Lexy Brodt]

--
Communicated by:
ProMED-mail
<promed@promedmail.org>

[Most people vaccinate horses in the spring, but the immunity to EEE wanes very quickly, and it is recommended to vaccinate approximately every 4 months to ensure that your animal is protected. - Mod.TG

A HealthMap/ProMED-mail map can be accessed at: http://healthmap.org/promed/p/250.]



See Also

Eastern equine encephalitis - USA (04): equine 20170726.5206247
Eastern equine encephalitis - USA (03): (SC) equine 20170725.5203111
Eastern equine encephalitis - USA (02): (GA) equine 20170722.5197500
Eastern equine encephalitis - USA: (FL) 20170121.4781360
2016
----
Eastern equine encephalitis - USA (28): (WI) equine 20161108.4615110
Eastern equine encephalitis - USA (27): (FL) equine 20161104.4607948
Eastern equine encephalitis - USA :(26) (SC, FL) equine 20161020.4573611
Eastern equine encephalitis - USA (25): (WI) equine 20161012.4553781
Eastern equine encephalitis - USA (24): (FL,WI) equine 20160922.4506635
Eastern equine encephalitis - USA (23): (WI) emus 20160921.4505968
Eastern equine encephalitis - USA (22): (WI,MI) equine 20160918.4496371
Eastern equine encephalitis - USA (21): (NJ,WI) equine 20160903.4462461
Eastern equine encephalitis - USA (20): (NC,NJ) equine, human 20160831.4453085
Eastern equine encephalitis - USA (19): equine 20160822.4432006
Eastern equine encephalitis - USA (18): (SC,TX) equine 20160818.4423685
Eastern equine encephalitis - USA (17): equine 20160813.4413695
Eastern equine encephalitis - USA (16): (FL,TN) equine 20160804.4394950
Eastern equine encephalitis - USA (15): (FL, SC) equine 20160728.4374635
Eastern equine encephalitis - USA (14): (FL,VA) equine 20160726.4369305
Eastern equine encephalitis - USA (13): (FL) equine 20160717.4350805
Eastern equine encephalitis - USA (09): (FL) equine 20160707.4330958
Eastern equine encephalitis - USA (07): (FL,SC,VA) equine 20160630.4319558
Eastern equine encephalitis - USA (03): (FL) equine 20160519.4233254
Eastern equine encephalitis - USA (02): (FL) equine 20160415.4162762
.................................................sb/tg/msp/dk

GDUFA Guidance Document/ Public Workshop on the Use of Real World Evidence

FDA/CDER's Small Business and Industry Assistance (CDER SBIA)

GDUFA Guidance Document/ Public Workshop on the Use of Real World Evidence

FDA has issued this guidance document to provide answers to questions arising from the implementation of the Generic Drug User Fee Amendments of 2012 (GDUFA). FDA is issuing the final guidance as two separate guidances. This guidance includes questions and answers related to self-identification, review of generic drug submissions, and inspections and compliance. It clarifies some of the questions and answers included in the previous versions based on FDA’s experience in implementing GDUFA. Questions and answers related to GDUFA’s user fee provisions that appeared in draft versions of this guidance appear in updated form in Guidance for Industry: Generic Drug User Fee Amendments of 2012: Questions and Answers Related to User Fee Assessments (Nov. 21, 2016). 
The questions and answers are grouped below in the following categories:
  • Self-identification of facilities, sites and organizations 
  • Review of generic drug submissions 
  • Inspections and compliance 
This guidance is one in a series of GDUFA communications. Other communications, including guidances and Federal Register notices are available on our GDUFA webpage.

The FDA is announcing the following public workshop entitled ‘‘Developing a Framework for Regulatory Use of Real-World Evidence.’’ Convened by the Duke-Robert J. Margolis, MD, Center for Health Policy at Duke University and supported by a cooperative agreement with FDA, the purpose of the public workshop is to bring the stakeholder community together to discuss a variety of topics related to the use of real-world data (RWD) and real-world evidence (RWE) in drug development and regulatory decision making. Topics will include an update on FDA’s activities to address the use of RWE in regulatory decisions and the development of a framework for tackling challenges related to RWE’s regulatory acceptability. In addition, panelists will discuss opportunities to improve data development activities, study designs, and analytical methods used to create robust RWE.
The public workshop will be held on September 13, 2017, from 9 AM to 4:30 PM Eastern Time at the Conference Center at 1777 F Street NW., Washington, DC 20006. There will also be a live webcast for those unable to attend the meeting in person.
For additional information, please refer to the following Web site: https://healthpolicy.duke.edu/events/publicworkshop-developing-frameworkregulatory-use-real-world-evidence  

Did You Know | AHRQ Patient Safety Network

Did You Know | AHRQ Patient Safety Network

PSNet email header



Did You Know Archive